Literature DB >> 8568138

Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism.

S Ikagawa1, S Matsushita, Y Z Chen, T Ishikawa, Y Nishimura.   

Abstract

We generated T cell clones specific to a Japanese cedar pollen allergen (Cry j 1) and investigated effects of altered T cell receptor (TCR) ligand on changes of T cell responses. One of these Cry j 1-specific T cell clones established from patients with Japanese cedar pollinosis, ST1.9, recognized an antigenic peptide Cry j 1 p335-346 in the context of HLA-DRA+DRB3*0301 molecules and secreted interleukin-4 dominantly, with a smaller amount of interferon-gamma. ST1.9 represented one of the major T cell clones specific to Cry j 1 in the donor, because a short-term cultured polyclonal T cell line specific to Cry j 1 exhibited the same character as the ST1.9. We synthesized various analog peptides derived from Cry j 1 p335-346 with single amino acid substitutions and determined key residues for interactions between TCR of ST1.9 and HLA-DR molecules. We also analyzed changes in the responses of ST1.9 to Cry j 1 p335-346-derived analog peptides. Of interest was that the substitution of 339threonine to valine resulted in a significant increase in interferon-gamma production, with no remarkable changes either in proliferative response or interleukin-4 production. Analog peptides carrying the substitutions of 339threonine to glycine or glutamine revealed TCR antagonism, without changes in their binding affinities to the DR molecule. Therefore single amino acid substitutions on an allergen peptide carrying the T cell epitope may suppress helper-T-dependent class switch pressure to IgE in B cells either by inducing increased interferon-gamma production or by inhibiting proliferative responses in helper-T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568138     DOI: 10.1016/s0091-6749(96)70283-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Immunodominance in allergic T-cell reactivity to Japanese cedar in different geographic cohorts.

Authors:  Carla Oseroff; John Pham; April Frazier; Denise Hinz; John Sidney; Sinu Paul; Jason A Greenbaum; Randi Vita; Bjoern Peters; Véronique Schulten; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

Review 2.  T cell recognition of weak ligands: roles of signaling, receptor number, and affinity.

Authors:  Lindsay J Edwards; Brian D Evavold
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

3.  The structure of HLA-DR52c: comparison to other HLA-DRB3 alleles.

Authors:  Shaodong Dai; Frances Crawford; Philippa Marrack; John W Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

Review 4.  Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases.

Authors:  Ayşe Kargili; Nüket Bavbek; Arif Kaya; Ali Koşar; Yaşar Karaaslan
Journal:  Rheumatol Int       Date:  2004-04-06       Impact factor: 2.631

5.  T-cell activation by transgenic rice seeds expressing the genetically modified Japanese cedar pollen allergens.

Authors:  Shinya Takaishi; Saburo Saito; Tomonori Endo; Daiya Asaka; Yuhya Wakasa; Hidenori Takagi; Kenjiro Ozawa; Fumio Takaiwa; Nobuyoshi Otori; Hiromi Kojima
Journal:  Immunology       Date:  2019-08-23       Impact factor: 7.397

Review 6.  On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).

Authors:  Martín Candia; Bernhard Kratzer; Winfried F Pickl
Journal:  Int Arch Allergy Immunol       Date:  2016-09-20       Impact factor: 2.749

7.  Polymorphisms in Cha o 1 and Cha o 2, major allergens of Japanese cypress (Chamaecyparis obtusa) pollen from a restricted region in Japan.

Authors:  Minoru Tateno; Ayaka Enami; Koji Fujinami; Hisashi Ohta
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.